Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Short term Debt (2016 - 2025)

Historic Short term Debt for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $2.0 million.

  • China Pharma Holdings' Short term Debt rose 8774.84% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 8774.84%. This contributed to the annual value of $1.1 million for FY2024, which is 98.57% up from last year.
  • Per China Pharma Holdings' latest filing, its Short term Debt stood at $2.0 million for Q3 2025, which was up 8774.84% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Short term Debt peaked at $4.3 million during Q3 2021, and registered a low of $1.0 million during Q3 2023.
  • For the 5-year period, China Pharma Holdings' Short term Debt averaged around $2.3 million, with its median value being $2.0 million (2021).
  • In the last 5 years, China Pharma Holdings' Short term Debt surged by 11247.69% in 2022 and then tumbled by 6673.43% in 2023.
  • Over the past 5 years, China Pharma Holdings' Short term Debt (Quarter) stood at $4.3 million in 2021, then tumbled by 43.61% to $2.4 million in 2022, then crashed by 53.55% to $1.1 million in 2023, then grew by 0.99% to $1.1 million in 2024, then skyrocketed by 70.82% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.4 million for Q2 2025, and $1.2 million during Q1 2025.